2月4日 - ** 英国细胞和基因疗法制造商牛津生物医学公司OXB.L股价上涨1.8%，报835便士
** 牛津生物医学公司表示，它扩大了与百时美施贵宝BNY.N的合作关系，签署了一项新的商业供应协议，为百时美施贵宝的CAR-T项目生产和供应慢病毒载体。
** 根据协议，OXB 预计待 CAR-T 产品获得监管部门批准后，于 2026 年开始商业化生产。
** 2025 年，OXB 公司上涨了 47%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.